Evidence map›Paper›PMID 37537121›Full record

ArticleThe Lancet. Digital health2023

Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study.

Samantha N Piekos, Yeon Mi Hwang, Ryan T Roper, Tanya Sorensen, Nathan D Price, Leroy Hood, Jennifer J Hadlock

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in The Lancet. Digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Effectiveness and Influence of COVID-19 Vaccination on Perinatal Individuals and Their Newborns: An Updated Meta-Analysis.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Samantha N PiekosInstitute for Systems Biology, Seattle, WA, USA.
Yeon Mi HwangInstitute for Systems Biology, Seattle, WA, USA.
Ryan T RoperInstitute for Systems Biology, Seattle, WA, USA.
Tanya SorensenSwedish Health Services, Swedish Medical Center, Seattle, WA, USA.
Nathan D PriceInstitute for Systems Biology, Seattle, WA, USA; Thorne HealthTech, New York, NY, USA.
Leroy HoodInstitute for Systems Biology, Seattle, WA, USA.
Jennifer J HadlockInstitute for Systems Biology, Seattle, WA, USA. Electronic address: jhadlock@isbscience.org.
Institute for Systems Biology · USSwedish Medical Center · US

Funding

Harnessing "omics": A Systems Biology approach to discovery of biologicalpathways in placental development and parturitionR01HD091527 · NICHD · UNIVERSITY OF FLORIDA · PI BALONI, PRIYANKA, JONES, HELEN N · 2017 to 2021
$2.7M
Enhancing personalized insights into common obstetric disorders using longitudinal deep-phenotyping dataK99HD112600 · NICHD · INSTITUTE FOR SYSTEMS BIOLOGY · PI PIEKOS, SAMANTHA · 2023 to 2024
$286k
NICHD NIH HHS K99 HD112600NICHD NIH HHS R01 HD091527
6 · The paper itself

Abstract

backgroundCOVID-19 in pregnant people increases the risk for poor maternal-fetal outcomes. However, COVID-19 vaccination hesitancy remains due to concerns over the vaccine's potential effects on maternal-fetal outcomes. Here we examine the impact of COVID-19 vaccination and boosters on maternal SARS-CoV-2 infections and birth outcomes.

methodsThis was a retrospective multicentre cohort study on the impact of COVID-19 vaccination on maternal-fetal outcomes for people who delivered (n=106 428) at Providence St Joseph Health across seven western US states from Jan 26, 2021 to Oct 26, 2022. Cohorts were defined by vaccination status at delivery: vaccinated (n=35 926; two or more doses of mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech), unvaccinated (n=55 878), unvaccinated propensity score matched (n=16 771), boosted (n=10 927; three or more doses), vaccinated unboosted (n=13 243; two doses only), and vaccinated unboosted with propensity score matching (n=4414). We built supervised machine learning classification models, which we used to determine which people were more likely to be vaccinated or boosted at delivery. The primary outcome was maternal SARS-CoV-2 infection. COVID-19 vaccination status at delivery, COVID-19-related health care, preterm birth, stillbirth, and very low birthweight were evaluated as secondary outcomes.

findingsVaccinated people were more likely to conceive later in the pandemic, have commercial insurance, be older, live in areas with lower household composition vulnerability, and have a higher BMI than unvaccinated people. Boosted people were more likely to have more days since receiving the second COVID-19 vaccine dose, conceive earlier in the pandemic, have commercial insurance, be older, and live in areas with lower household composition vulnerability than vaccinated unboosted people. Vaccinated pregnant people had lower rates of COVID-19 during pregnancy (4·0%) compared with unvaccinated matched people (5·3%; p<0·0001). COVID-19 rates were even lower in boosted people (3·2%) compared with vaccinated unboosted matched people (5·6%; p<0·0001). Vaccinated people were also less likely to have a preterm birth (7·9%; p<0·0001), stillbirth (0·3%; p<0·0002), or very low birthweight neonate (1·0%; p<0·0001) compared with unvaccinated matched people (preterm birth 9·4%; stillbirth 0·6%; very low birthweight 1·5%). Boosted people were less likely to have a stillbirth (0·3%; p<0·025) and have no differences in rates of preterm birth (7·6%; p=0·090) or very low birthweight neonates (0·8%; p=0·092) compared with vaccinated unboosted matched people (stillbirth 0·5%; preterm birth 8·4%; very low birthweight 1·1%).

interpretationCOVID-19 vaccination protects against adverse maternal-fetal outcomes, with booster doses conferring additional protection. Pregnant people should be high priority for vaccination and stay up to date with their COVID-19 vaccination schedule.

fundingNational Institute for Child Health & Human Development and the William O and K Carole Ellison Foundation.

Indexed as

COVID-19Premature BirthBNT162 VaccineChildCohort StudiesCOVID-19 VaccinesFemaleHumansInfant, NewbornPregnancyRetrospective StudiesSARS-CoV-2StillbirthBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID37537121
PMCPMC10473855
OpenAlexW4385449054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.